NCT03906513View on ClinicalTrials.gov

Evaluation of the Efficacy of OMK2 in Recovering Corneal Neural Damage in Patients With Diabetes

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

May 3, 2017

Study Completion Date

January 17, 2019

Conditions
Cornea
Interventions
DEVICE

OMK2

OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).

Trial Locations (1)

20142

ASST Santi Paolo e Carlo - Ospedale San Paolo, Milan

All Listed Sponsors
lead

University of Milan

OTHER

NCT03906513 - Evaluation of the Efficacy of OMK2 in Recovering Corneal Neural Damage in Patients With Diabetes | Biotech Hunter | Biotech Hunter